請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37154
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳振陽(Jen-Yang Chen) | |
dc.contributor.author | Yi-Ren Chen | en |
dc.contributor.author | 陳逸人 | zh_TW |
dc.date.accessioned | 2021-06-13T15:20:13Z | - |
dc.date.available | 2010-08-08 | |
dc.date.copyright | 2008-08-08 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-23 | |
dc.identifier.citation | Abramova NA, Russell J, Botchan M, Li R. 1997. Interaction between replication protein A and p53 is disrupted after UV damage in a DNA repair-dependent manner. Proc Natl Acad Sci U S A 94(14):7186-7191.
Adimoolam S, Ford JM. 2002. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci U S A 99(20):12985-12990. Anderson MJ, Viars CS, Czekay S, Cavenee WK, Arden KC. 1998. Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics 47(2):187-199. Arden KC. 2006. Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer. Exp Gerontol 41(8):709-717. Atkinson PG, Coope HJ, Rowe M, Ley SC. 2003. Latent membrane protein 1 of Epstein-Barr virus stimulates processing of NF-kappa B2 p100 to p52. J Biol Chem 278(51):51134-51142. Bader AG, Kang S, Zhao L, Vogt PK. 2005. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5(12):921-929. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Seguin C, et al. 1984. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310(5974):207-211. Baichwal VR, Sugden B. 1988. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2(5):461-467. Bakker WJ, Blazquez-Domingo M, Kolbus A, Besooyen J, Steinlein P, Beug H, Coffer PJ, Lowenberg B, von Lindern M, van Dijk TB. 2004. FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1. J Cell Biol 164(2):175-184. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, Testa JR. 1995. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64(4):280-285. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. 1991. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254(5029):274-277. Biggs WH, 3rd, Cavenee WK, Arden KC. 2001. Identification and characterization of members of the FKHR (FOX O) subclass of winged-helix transcription factors in the mouse. Mamm Genome 12(6):416-425. Biggs WH, 3rd, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. 1999. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A 96(13):7421-7426. Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signalling. Nature 411(6835):355-365. Borkhardt A, Repp R, Haas OA, Leis T, Harbott J, Kreuder J, Hammermann J, Henn T, Lampert F. 1997. Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23). Oncogene 14(2):195-202. Brennan P, Floettmann JE, Mehl A, Jones M, Rowe M. 2001. Mechanism of action of a novel latent membrane protein-1 dominant negative. J Biol Chem 276(2):1195-1203. Brodeur SR, Cheng G, Baltimore D, Thorley-Lawson DA. 1997. Localization of the major NF-kappaB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. J Biol Chem 272(32):19777-19784. Brooks L, Yao QY, Rickinson AB, Young LS. 1992. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 66(5):2689-2697. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96(6):857-868. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. 2001. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 21(3):952-965. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME. 2004. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303(5666):2011-2015. Buchhop S, Gibson MK, Wang XW, Wagner P, Sturzbecher HW, Harris CC. 1997. Interaction of p53 with the human Rad51 protein. Nucleic Acids Res 25(19):3868-3874. Burke AP, Yen TS, Shekitka KM, Sobin LH. 1990. Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol 3(3):377-380. Burkitt DA. 1958. A sarcoma involving the jaws in African children. Brit J Surg 45:218-223. Butel JS, Lee TH, Slagle BL. 1996. Is the DNA repair system involved in hepatitis-B-virus-mediated hepatocellular carcinogenesis? Trends Microbiol 4(3):119-124. Capovilla A, Carmona S, Arbuthnot P. 1997. Hepatitis B virus X-protein binds damaged DNA and sensitizes liver cells to ultraviolet irradiation. Biochem Biophys Res Commun 232(1):255-260. Castrillon DH, Miao L, Kollipara R, Horner JW, DePinho RA. 2003. Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science 301(5630):215-218. Chang Y, Cheng SD, Tsai CH. 2002. Chromosomal integration of Epstein-Barr virus genomes in nasopharyngeal carcinoma cells. Head Neck 24(2):143-150. Chang Y, Tung CH, Huang YT, Lu J, Chen JY, Tsai CH. 1999. Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes. J Virol 73(10):8857-8866. Chen CL, Sadler RH, Walling DM, Su IJ, Hsieh HC, Raab-Traub N. 1993. Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol 67(10):6303-6308. Chen H, Lee JM, Zong Y, Borowitz M, Ng MH, Ambinder RF, Hayward SD. 2001a. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J Virol 75(6):2929-2937. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK. 2001b. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20(42):6073-6083. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR. 1996. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A 93(8):3636-3641. Chevallier-Greco A, Manet E, Chavrier P, Mosnier C, Daillie J, Sergeant A. 1986. Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J 5(12):3243-3249. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, Yang CS. 2001. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 345(26):1877-1882. Chu G, Chang. E. 1988. Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. Science 242:564-567. Clough W. 1979. Deoxyribonuclease activity found in Epstein--Barr virus producing lymphoblastoid cells. Biochemistry 18(21):4517-4521. Coffer PJ, Woodgett JR. 1991. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 201(2):475-481. Countryman J, Jenson H, Seibl R, Wolf H, Miller G. 1987. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol 61(12):3672-3679. Countryman J, Miller G. 1985. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A 82(12):4085-4089. Cox MA, Leahy J, Hardwick JM. 1990. An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J Virol 64(1):313-321. Cunningham L, Bowles NE, Archard LC. 1991. Persistent virus infection of muscle in postviral fatigue syndrome. Br Med Bull 47(4):852-871. D'Souza B, Rowe M, Walls D. 2000. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line. J Virol 74(14):6652-6658. Dambaugh T, Beisel C, Hummel M, King W, Fennewald S, Cheung A, Heller M, Raab-Traub N, Kieff E. 1980. Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci U S A 77(5):2999-3003. Dan HC, Sun M, Yang L, Feldman RI, Sui XM, Ou CC, Nellist M, Yeung RS, Halley DJ, Nicosia SV, Pledger WJ, Cheng JQ. 2002. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 277(38):35364-35370. Datta A, Bagchi S, Nag A, Shiyanov P, Adami GR, Yoon T, Raychaudhuri P. 2001. The p48 subunit of the damaged-DNA binding protein DDB associates with the CBP/p300 family of histone acetyltransferase. Mutat Res 486(2):89-97. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. 1994. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 54(11):2869-2872. Dawson CW, Laverick L, Morris MA, Tramoutanis G, Young LS. 2008. Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway. J Virol 82(7):3654-3664. Dawson CW, Rickinson AB, Young LS. 1990. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 344(6268):777-780. Dawson CW, Tramountanis G, Eliopoulos AG, Young LS. 2003. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem 278(6):3694-3704. de Vries A, van Oostrom CT, Hofhuis FM, Dortant PM, Berg RJ, de Gruijl FR, Wester PW, van Kreijl CF, Capel PJ, van Steeg H, et al. 1995. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 377(6545):169-173. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. 1998. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A 95(19):11211-11216. Devergne O, Cahir McFarland ED, Mosialos G, Izumi KM, Ware CF, Kieff E. 1998. Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 72(10):7900-7908. Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, Mosialos G. 1996. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 16(12):7098-7108. Diehl JA, Cheng M, Roussel MF, Sherr CJ. 1998. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12(22):3499-3511. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. 2000. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10(19):1201-1204. Dolyniuk M, Pritchett R, Kieff E. 1976. Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus. J Virol 17(3):935-949. Dualan R, Brody T, Keeney S, Nichols AF, Admon A, Linn S. 1995. Chromosomal localization and cDNA cloning of the genes (DDB1 and DDB2) for the p127 and p48 subunits of a human damage-specific DNA binding protein. Genomics 29(1):62-69. Duensing S, Munger K. 2002. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 62(23):7075-7082. Eliopoulos AG, Blake SM, Floettmann JE, Rowe M, Young LS. 1999a. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol 73(2):1023-1035. Eliopoulos AG, Caamano JH, Flavell J, Reynolds GM, Murray PG, Poyet JL, Young LS. 2003. Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway. Oncogene 22(48):7557-7569. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS. 1999b. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 274(23):16085-16096. Eliopoulos AG, Young LS. 1998. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 16(13):1731-1742. Eliopoulos AG, Young LS. 2001. LMP1 structure and signal transduction. Semin Cancer Biol 11(6):435-444. Epstein MA, Achong BG, Barr YM. 1964. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1(7335):702-703. Epstein MA, Barr YM. 1964. Cultivation in vitro of human lymphoblasts from Burkitt's malignant lymphoma. Lancet 1(7327):252-253. Essers MA, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, Bos JL, Burgering BM. 2004. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. Embo J 23(24):4802-4812. Everly DN, Jr., Mainou BA, Raab-Traub N. 2004. Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. J Virol 78(24):13470-13478. Fahraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, Falk K, Nilsson E, Yadav M, Busson P, et al. 1988. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 42(3):329-338. Fielding CA, Sandvej K, Mehl A, Brennan P, Jones M, Rowe M. 2001. Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. J Virol 75(19):9129-9141. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. 2004. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30(2):193-204. Fruman DA, Meyers RE, Cantley LC. 1998. Phosphoinositide kinases. Annu Rev Biochem 67:481-507. Fukuoka M, Daitoku H, Hatta M, Matsuzaki H, Umemura S, Fukamizu A. 2003. Negative regulation of forkhead transcription factor AFX (Foxo4) by CBP-induced acetylation. Int J Mol Med 12(4):503-508. Furnari FB, Huang HJ, Cavenee WK. 1998. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 58(22):5002-5008. Furuyama T, Kitayama K, Shimoda Y, Ogawa M, Sone K, Yoshida-Araki K, Hisatsune H, Nishikawa S, Nakayama K, Ikeda K, Motoyama N, Mori N. 2004. Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem 279(33):34741-34749. Furuyama T, Nakazawa T, Nakano I, Mori N. 2000. Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem J 349(Pt 2):629-634. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ, 3rd, Emanuel BS, Rovera G, Barr FG. 1993. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 5(3):230-235. Garrington TP, Johnson GL. 1999. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 11(2):211-218. Gerber P, Lucas S, Nonoyama M, Perlin E, Goldstein LI. 1972. Oral excretion of Epstein-Barr virus by healthy subjects and patients with infectious mononucleosis. Lancet 2(7785):988-989. Gilley J, Coffer PJ, Ham J. 2003. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 162(4):613-622. Gires O, Kohlhuber F, Kilger E, Baumann M, Kieser A, Kaiser C, Zeidler R, Scheffer B, Ueffing M, Hammerschmidt W. 1999. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J 18(11):3064-3073. Gires O, Zimber-Strobl U, Gonnella R, Ueffing M, Marschall G, Zeidler R, Pich D, Hammerschmidt W. 1997. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J 16(20):6131-6140. Glaser R, Ogino T, Zimmerman J, Jr., Rapp F. 1973. Thymidine kinase activity in Burkitt lymphoblastoid somatic cell hybrids after induction of the EB virus. Proc Soc Exp Biol Med 142(4):1059-1062. Greer EL, Brunet A. 2005. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24(50):7410-7425. Gualandi G, Giselico L, Carloni M, Palitti F, Mosesso P, Alfonsi AM. 2001. Enhancement of genetic instability in human B cells by Epstein-Barr virus latent infection. Mutagenesis 16(3):203-208. Haan KM, Kwok WW, Longnecker R, Speck P. 2000. Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor. J Virol 74(5):2451-2454. Haddad RS, Hutt-Fletcher LM. 1989. Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells. J Virol 63(12):4998-5005. Hampar B, Derge JG, Martos LM, Walker JL. 1971. Persistence of a repressed Epstein-Barr virus genome in Burkitt lymphoma cells made resistant to 5-bromodeoxyuridine. Proc Natl Acad Sci U S A 68(12):3185-3189. Harari D, Yarden Y. 2000. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19(53):6102-6114. Hatzivassiliou E, Miller WE, Raab-Traub N, Kieff E, Mosialos G. 1998. A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase. J Immunol 160(3):1116-1121. He Z, Xin B, Yang X, Chan C, Cao L. 2000. Nuclear factor-kappaB activation is involved in LMP1-mediated transformation and tumorigenesis of rat-1 fibroblasts. Cancer Res 60(7):1845-1848. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A. 1991. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65(7):1107-1115. Henle G, Henle W. 1966. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol 91(3):1248-1256. Henle G, Henle W. 1976. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17(1):1-7. Henle G, Henle W, Diehl V. 1968. Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci U S A 59(1):94-101. Hennessy K, Fennewald S, Hummel M, Cole T, Kieff E. 1984. A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proc Natl Acad Sci U S A 81(22):7207-7211. Heuvel APJvd. 2004. Analysis of the protein kinase B [Oncology]. Utrecht: University Medical Center Utrecht. 104 p. Hillion J, Le Coniat M, Jonveaux P, Berger R, Bernard OA. 1997. AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily. Blood 90(9):3714-3719. Hino O, Tabata S, Hotta Y. 1991. Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. Proc Natl Acad Sci U S A 88(20):9248-9252. Hoeijmakers JH. 2001. Genome maintenance mechanisms for preventing cancer. Nature 411(6835):366-374. Hong SY, Yoon WH, Park JH, Kang SG, Ahn JH, Lee TH. 2000. Involvement of two NF-kappa B binding elements in tumor necrosis factor alpha -, CD40-, and epstein-barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. J Biol Chem 275(24):18022-18028. Hosaka T, Biggs WH, 3rd, Tieu D, Boyer AD, Varki NM, Cavenee WK, Arden KC. 2004. Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc Natl Acad Sci U S A 101(9):2975-2980. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R, Hung MC. 2004. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117(2):225-237. Huang DP, Ho JH, Chan WK, Lau WH, Lui M. 1989. Cytogenetics of undifferentiated nasopharyngeal carcinoma xenografts from southern Chinese. Int J Cancer 43(5):936-939. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, Tindall DJ. 2005. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A 102(5):1649-1654. Huen DS, Henderson SA, Croom-Carter D, Rowe M. 1995. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10(3):549-560. Hunter T. 2000. Signaling--2000 and beyond. Cell 100(1):113-127. Hwang BJ, Ford JM, Hanawalt PC, Chu G. 1999. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci U S A 96(2):424-428. Hwang BJ, Liao JC, Chu G. 1996. Isolation of a cDNA encoding a UV-damaged DNA binding factor defective in xeroderma pigmentosum group E cells. Mutat Res 362(1):105-117. Hwang BJ, Toering S, Francke U, Chu G. 1998. p48 Activates a UV-damaged-DNA binding factor and is defective in xeroderma pigmentosum group E cells that lack binding activity. Mol Cell Biol 18(7):4391-4399. Hwang JK, Lin CT. 1997. Co-localization of endogenous and exogenous p53 proteins in nasopharyngeal carcinoma cells. J Histochem Cytochem 45(7):991-1003. Imai S, Nishikawa J, Takada K. 1998. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol 72(5):4371-4378. Inoki K, Li Y, Zhu T, Wu J, Guan KL. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4(9):648-657. Izumi KM, Cahir McFarland ED, Ting AT, Riley EA, Seed B, Kieff ED. 1999. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation. Mol Cell Biol 19(8):5759-5767. Izumi KM, Kaye KM, Kieff ED. 1997. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci U S A 94(4):1447-1452. Izumi KM, Kieff ED. 1997. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci U S A 94(23):12592-12597. Jackson JG, Kreisberg JI, Koterba AP, Yee D, Brattain MG. 2000. Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. Oncogene 19(40):4574-4581. Jia L, Wang XW, Harris CC. 1999. Hepatitis B virus X protein inhibits nucleotide excision repair. Int J Cancer 80(6):875-879. Jones JF, Shurin S, Abramowsky C, Tubbs RR, Sciotto CG, Wahl R, Sands J, Gottman D, Katz BZ, Sklar J. 1988. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med 318(12):733-741. Jones PF, Jakubowicz T, Pitossi FJ, Maurer F, Hemmings BA. 1991. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A 88(10):4171-4175. Jonsson H, Allen P, Peng SL. 2005. Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis. Nat Med 11(6):666-671. Kaestner KH, Knochel W, Martinez DE. 2000. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev 14(2):142-146. Kallin B, Sternas L, Saemundssen AK, Luka J, Jornvall H, Eriksson B, Tao PZ, Nilsson MT, Klein G. 1985. Purification of Epstein-Barr virus DNA polymerase from P3HR-1 cells. J Virol 54(2):561-568. Kandasamy K, Srivastava RK. 2002. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 62(17):4929-4937. Kao SY, Lemoine FJ, Marriott SJ. 2000. Suppression of DNA repair by human T cell leukemia virus type 1 Tax is rescued by a functional p53 signaling pathway. J Biol Chem 275(46):35926-35931. Kao SY, Marriott SJ. 1999. Disruption of nucleotide excision repair by the human T-cell leukemia virus type 1 Tax protein. J Virol 73(5):4299-4304. Kashii Y, Uchida M, Kirito K, Tanaka M, Nishijima K, Toshima M, Ando T, Koizumi K, Endoh T, Sawada K, Momoi M, Miura Y, Ozawa K, Komatsu N. 2000. A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. Blood 96(3):941-949. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G. 1997. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385(6616):544-548. Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E, Mosialos G. 1996. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci U S A 93(20):11085-11090. Kaye KM, Izumi KM, Kieff E. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A 90(19):9150-9154. Kaye KM, Izumi KM, Li H, Johannsen E, Davidson D, Longnecker R, Kieff E. 1999. An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation. J Virol 73(12):10525-10530. Keeney S, Chang GJ, Linn S. 1993. Characterization of a human DNA damage binding protein implicated in xeroderma pigmentosum E. J Biol Chem 268(28):21293-21300. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W. 1997. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. Embo J 16(21):6478-6485. Kikuta H, Taguchi Y, Tomizawa K, Kojima K, Kawamura N, Ishizaka A, Sakiyama Y, Matsumoto S, Imai S, Kinoshita T, et al. 1988. Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature 333(6172):455-457. Kim KR, Yoshizaki T, Miyamori H, Hasegawa K, Horikawa T, Furukawa M, Harada S, Seiki M, Sato H. 2000. Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth. Oncogene 19(14):1764-1771. Kino T, De Martino MU, Charmandari E, Ichijo T, Outas T, Chrousos GP. 2005. HIV-1 accessory protein Vpr inhibits the effect of insulin on the FOXO subfamily of forkhead transcription factors by interfering with their binding to 14-3-3 proteins: potential clinical implications regarding the insulin resistance of HIV-1-infected patients. Diabetes 54(1):23-31. Klein G, Clifford P, Klein E, Stjernsward J. 1966. Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. Proc Natl Acad Sci U S A 55(6):1628-1635. Kops GJ, Burgering BM. 1999. Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med 77(9):656-665. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, Burgering BM. 2002a. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419(6904):316-321. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ, Lam EW, Burgering BM. 2002b. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 22(7):2025-2036. Kuhn-Hallek I, Sage DR, Stein L, Groelle H, Fingeroth JD. 1995. Expression of recombination activating genes (RAG-1 and RAG-2) in Epstein-Barr virus-bearing B cells. Blood 85(5):1289-1299. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N. 1998. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci U S A 95(20):11963-11968. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM. 1992. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 267(34):24157-24160. Lee TH, Elledge SJ, Butel JS. 1995. Hepatitis B virus X protein interacts with a probable cellular DNA repair protein. J Virol 69(2):1107-1114. Leveillard T, Andera L, Bissonnette N, Schaeffer L, Bracco L, Egly JM, Wasylyk B. 1996. Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J 15(7):1615-1624. Li HP, Chang YS. 2003. Epstein-Barr virus latent membrane protein 1: structure and functions. J Biomed Sci 10(5):490-504. Li Q, Spriggs MK, Kovats S, Turk SM, Comeau MR, Nepom B, Hutt-Fletcher LM. 1997. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol 71(6):4657-4662. Li QX, Young LS, Niedobitek G, Dawson CW, Birkenbach M, Wang F, Rickinson AB. 1992. Epstein-Barr virus infection and replication in a human epithelial cell system. Nature 356(6367):347-350. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM. 2002. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8(10):1153-1160. Liebowitz D, Kopan R, Fuchs E, Sample J, Kieff E. 1987. An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes. Mol Cell Biol 7(7):2299-2308. Liebowitz D, Mannick J, Takada K, Kieff E. 1992. Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells. J Virol 66(7):4612-4616. Liebowitz D, Wang D, Kieff E. 1986. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol 58(1):233-237. Lin CT, Chan WY, Chen W, Huang HM, Wu HC, Hsu MM, Chuang SM, Wang CC. 1993. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab Invest 68(6):716-727. Lin CT, Kao HJ, Lin JL, Chan WY, Wu HC, Liang ST. 2000. Response of nasopharyngeal carcinoma cells to Epstein-Barr virus infection in vitro. Lab Invest 80(8):1149-1160. Lin CT, Wong CI, Chan WY, Tzung KW, Ho JK, Hsu MM, Chuang SM. 1990. Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab Invest 62(6):713-724. Lin GY, Lamb RA. 2000. The paramyxovirus simian virus 5 V protein slows progression of the cell cycle. J Virol 74(19):9152-9166. Lin GY, Paterson RG, Richardson CD, Lamb RA. 1998. The V protein of the paramyxovirus SV5 interacts with damage-specific DNA binding protein. Virology 249(1):189-200. Lin SY, Tsang NM, Kao SC, Hsieh YL, Chen YP, Tsai CS, Kuo TT, Hao SP, Chen IH, Hong JH. 2001. Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma. Head Neck 23(3):194-200. Lindahl T, Adams A, Bjursell G, Bornkamm GW, Kaschka-Dierich C, Jehn U. 1976. Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line. J Mol Biol 102(3):511-530. Littler E, Arrand JR. 1988. Characterization of th | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37154 | - |
dc.description.abstract | EB病毒(Epstein-Barr virus, EBV)的潛伏膜蛋白1(latent membrane protein 1, LMP1)被視為是致癌蛋白,因其可模擬持續活化的腫瘤壞死因子受體(tumor necrosis factor receptor)且觸發包括phosphatidylinositol 3-kinase (PI3K)/Akt在內的數條訊號傳遞路徑。此外LMP1亦可致使數種細胞株轉形並且對EBV所造成之B細胞轉形為必需。細胞轉形與基因體不穩定有高度關聯性,其中細胞之DNA修復系統對於基因體之穩定性扮演重要的角色。在過去之研究中,我們已經發現到LMP1可透過其CTAR1區域抑制表皮細胞之DNA修復。在本篇研究中,我們進一步證明LMP1透過CTAR1區域觸發PI3K/Akt這條訊號傳遞路徑,進而造成細胞DNA修復之抑制。此外,藉由此路徑之活化,過去曾被證明可促進細胞DNA修復之FOXO3a轉錄因子,亦會受到磷酸化之影響而改變其在細胞內之位置。而另一參與核苷酸切除修復(nucleotide excision repair)且受到FOXO3a轉錄因子所調控之DDB1蛋白,也會因此降低表現量。反之,當回補FOXO3a或DDB1時, 此LMP1抑制DNA修復之現象可獲緩解。這些結果顯示,LMP1乃透過其CTAR1區域觸發PI3K/Akt訊號傳遞路徑,進而使FOXO3a轉錄因子不活化,接著使DNA修復蛋白質DDB1之表現降低,最終致使細胞DNA修復能力之抑制。而此現象有可能會造成基因體之不穩定,進而引導細胞走向癌化。 | zh_TW |
dc.description.abstract | Latent membrane protein 1 (LMP1), an Epstein-Barr virus (EBV) oncoprotein, mimics a constitutively activated tumor necrosis factor receptor and activates various signaling pathways including phosphatidylinositol 3-kinase (PI3K)/Akt. LMP1 is essential for EBV-mediated B-cell transformation and is sufficient to transform several cell lines. Cellular transformation has been associated strongly with genomic instability, while DNA repair plays an important role in maintaining genomic stability. Previously, we have shown that LMP1 represses DNA repair by the C-terminal activating region 1 (CTAR1) in human epithelial cells. In the present study, we demonstrate that the PI3K/Akt pathway is required for LMP1-mediated repression of DNA repair. Through the LMP1/PI3K/Akt pathway, FOXO3a, which can induce DNA repair, is inactivated because of phosphorylation and relocalization. Expression of a constitutively active FOXO3a mutant can rescue LMP1-mediated repression of DNA repair. Furthermore, LMP1 can decrease the expression of DNA damage-binding protein 1 (DDB1), which functions in nucleotide excision repair, through the PI3K/Akt/FOXO3a pathway. LMP1-mediated repression of DNA repair is restored by DDB1, although only partially. These results suggest that LMP1 triggers the PI3K/Akt pathway to inactivate FOXO3a and decrease DDB1, which can lead to repression of DNA repair and may contribute to genomic instability in human epithelial cells. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T15:20:13Z (GMT). No. of bitstreams: 1 ntu-97-D92445007-1.pdf: 4909709 bytes, checksum: 454a1ce005e2c7517ba3366bf919fdea (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 口試委員會審定書……………………………………………………i
誌謝……………………………………………………………………ii 中文摘要………………………………………………………………iii 英文摘要………………………………………………………………iv 序論……………………………………………………………………1 一、EB病毒……………………………………………………………1 二、EB病毒之潛伏膜蛋白1…………………………………………9 三、PI3K/Akt訊號傳遞路徑………………………………………14 四、FOXO轉錄因子…………………………………………………18 五、DNA損傷與DNA修復系統………………………………………23 六、紫外線損傷DNA結合蛋白……………………………………26 實驗目的………………………………………………………………29 實驗材料與方法………………………………………………………31 一、材料………………………………………………………………31 二、方法………………………………………………………………40 實驗結果………………………………………………………………45 實驗討論………………………………………………………………53 結論……………………………………………………………………62 未來工作………………………………………………………………63 圖………………………………………………………………………65 參考文獻………………………………………………………………94 附錄……………………………………………………………………133 | |
dc.language.iso | zh-TW | |
dc.title | EB病毒之潛伏膜蛋白1透過PI3K/Akt/FOXO3a路徑抑制人類表皮細胞的DNA修復能力 | zh_TW |
dc.title | Epstein-Barr Virus Latent Membrane Protein 1 Represses DNA Repair through the PI3K/Akt/FOXO3a Pathway in Human Epithelial Cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 許翠瑛,王萬波,陳美如,李財坤,林素芳 | |
dc.subject.keyword | EB病毒,潛伏膜蛋白1,PI3K/Akt訊號傳遞路徑,FOXO3a轉錄因子,DNA修復蛋白質DDB1,基因體不穩定性, | zh_TW |
dc.subject.keyword | EBV,LMP1,PI3K/Akt signaling pathway,FOXO3a,DDB1,DNA repair,Genomic instability, | en |
dc.relation.page | 142 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-07-24 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 4.79 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。